These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 32718999)

  • 21. The Hsp70 inhibiting peptide aptamer A17 potentiates radiosensitization of tumor cells by Hsp90 inhibition.
    Schilling D; Garrido C; Combs SE; Multhoff G
    Cancer Lett; 2017 Apr; 390():146-152. PubMed ID: 28108313
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel HSP90 inhibitor with reduced hepatotoxicity synergizes with radiotherapy to induce apoptosis, abrogate clonogenic survival, and improve tumor control in models of colorectal cancer.
    Kinzel L; Ernst A; Orth M; Albrecht V; Hennel R; Brix N; Frey B; Gaipl US; Zuchtriegel G; Reichel CA; Blutke A; Schilling D; Multhoff G; Li M; Niyazi M; Friedl AA; Winssinger N; Belka C; Lauber K
    Oncotarget; 2016 Jul; 7(28):43199-43219. PubMed ID: 27259245
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy.
    Yin X; Zhang H; Lundgren K; Wilson L; Burrows F; Shores CG
    Int J Cancer; 2010 Mar; 126(5):1216-25. PubMed ID: 19662650
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Heat Shock Protein 90 Inhibitor, AT13387, Protects the Alveolo-Capillary Barrier and Prevents HCl-Induced Chronic Lung Injury and Pulmonary Fibrosis.
    Colunga Biancatelli RML; Solopov P; Dimitropoulou C; Gregory B; Day T; Catravas JD
    Cells; 2022 Mar; 11(6):. PubMed ID: 35326496
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hsp90 inhibitor-mediated disruption of chaperone association of ATR with hsp90 sensitizes cancer cells to DNA damage.
    Ha K; Fiskus W; Rao R; Balusu R; Venkannagari S; Nalabothula NR; Bhalla KN
    Mol Cancer Ther; 2011 Jul; 10(7):1194-206. PubMed ID: 21566061
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The HSP90 inhibitor onalespib potentiates 177Lu‑DOTATATE therapy in neuroendocrine tumor cells.
    Lundsten S; Spiegelberg D; Stenerlöw B; Nestor M
    Int J Oncol; 2019 Dec; 55(6):1287-1295. PubMed ID: 31638190
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dual PI3K- and mTOR-inhibitor PI-103 can either enhance or reduce the radiosensitizing effect of the Hsp90 inhibitor NVP-AUY922 in tumor cells: The role of drug-irradiation schedule.
    Djuzenova CS; Fiedler V; Katzer A; Michel K; Deckert S; Zimmermann H; Sukhorukov VL; Flentje M
    Oncotarget; 2016 Jun; 7(25):38191-38209. PubMed ID: 27224913
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting DNA damage response in head and neck cancers through abrogation of cell cycle checkpoints.
    Molkentine JM; Molkentine DP; Bridges KA; Xie T; Yang L; Sheth A; Heffernan TP; Clump DA; Faust AZ; Ferris RL; Myers JN; Frederick MJ; Mason KA; Meyn RE; Pickering CR; Skinner HD
    Int J Radiat Biol; 2021; 97(8):1121-1128. PubMed ID: 32073931
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HSP90 inhibition sensitizes head and neck cancer to platin-based chemoradiotherapy by modulation of the DNA damage response resulting in chromosomal fragmentation.
    McLaughlin M; Barker HE; Khan AA; Pedersen M; Dillon M; Mansfield DC; Patel R; Kyula JN; Bhide SA; Newbold KL; Nutting CM; Harrington KJ
    BMC Cancer; 2017 Jan; 17(1):86. PubMed ID: 28143445
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radiosensitization of HSF-1 Knockdown Lung Cancer Cells by Low Concentrations of Hsp90 Inhibitor NVP-AUY922.
    Kühnel A; Schilling D; Combs SE; Haller B; Schwab M; Multhoff G
    Cells; 2019 Sep; 8(10):. PubMed ID: 31569342
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radiation Enhancement of Head and Neck Squamous Cell Carcinoma by the Dual PI3K/mTOR Inhibitor PF-05212384.
    Leiker AJ; DeGraff W; Choudhuri R; Sowers AL; Thetford A; Cook JA; Van Waes C; Mitchell JB
    Clin Cancer Res; 2015 Jun; 21(12):2792-801. PubMed ID: 25724523
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Induction of Hsp70 in tumor cells treated with inhibitors of the Hsp90 activity: A predictive marker and promising target for radiosensitization.
    Kudryavtsev VA; Khokhlova AV; Mosina VA; Selivanova EI; Kabakov AE
    PLoS One; 2017; 12(3):e0173640. PubMed ID: 28291803
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of Hsp90: a multitarget approach to radiosensitization.
    Camphausen K; Tofilon PJ
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4326-30. PubMed ID: 17671112
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Radiosensitization approaches for HPV-positive and HPV-negative head and neck squamous carcinomas.
    Dok R; Bamps M; Glorieux M; Zhao P; Sablina A; Nuyts S
    Int J Cancer; 2020 Feb; 146(4):1075-1085. PubMed ID: 31283004
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer cells.
    Gandhi N; Wild AT; Chettiar ST; Aziz K; Kato Y; Gajula RP; Williams RD; Cades JA; Annadanam A; Song D; Zhang Y; Hales RK; Herman JM; Armour E; DeWeese TL; Schaeffer EM; Tran PT
    Cancer Biol Ther; 2013 Apr; 14(4):347-56. PubMed ID: 23358469
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Total synthesis of resorcinol amide Hsp90 inhibitor AT13387.
    Patel BH; Barrett AG
    J Org Chem; 2012 Dec; 77(24):11296-301. PubMed ID: 23186098
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase Ib study of HSP90 inhibitor, onalespib (AT13387), in combination with paclitaxel in patients with advanced triple-negative breast cancer.
    Williams NO; Quiroga D; Johnson C; Brufsky A; Chambers M; Bhattacharya S; Patterson M; Sardesai SD; Stover D; Lustberg M; Noonan AM; Cherian M; Bystry DM; Hill KL; Chen M; Phelps MA; Grever M; Stephens JA; Ramaswamy B; Carson WE; Wesolowski R
    Ther Adv Med Oncol; 2023; 15():17588359231217976. PubMed ID: 38152697
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Radioresistant human lung adenocarcinoma cells that survived multiple fractions of ionizing radiation are sensitive to HSP90 inhibition.
    Gomez-Casal R; Epperly MW; Wang H; Proia DA; Greenberger JS; Levina V
    Oncotarget; 2015 Dec; 6(42):44306-22. PubMed ID: 26517240
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Wild-type EGFR is stabilized by direct interaction with HSP90 in cancer cells and tumors.
    Ahsan A; Ramanand SG; Whitehead C; Hiniker SM; Rehemtulla A; Pratt WB; Jolly S; Gouveia C; Truong K; Van Waes C; Ray D; Lawrence TS; Nyati MK
    Neoplasia; 2012 Aug; 14(8):670-7. PubMed ID: 22952420
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined EGFR1 and PARP1 Inhibition Enhances the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Models.
    Frederick BA; Gupta R; Atilano-Roque A; Su TT; Raben D
    Radiat Res; 2020 Nov; 194(5):519-531. PubMed ID: 32936912
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.